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ABSTRACT The bone metastasis-derived PC3 and the lymph node metastasis-derived LNCaP prostate
cancer cell lines are widely studied, having been described in thousands of publications over the last four
decades. Here, we report short-read whole-genome sequencing (WGS) and de novo assembly of PC3
(ATCC CRL-1435) and LNCaP (clone FGC; ATCC CRL-1740) at 70 · coverage. A known homozygous
mutation in TP53 and homozygous loss of PTEN were robustly identiﬁed in the PC3 cell line, whereas the
LNCaP cell line exhibited a larger number of putative inactivating somatic point and indel mutations (and in
particular a loss of stop codon events). This study also provides preliminary evidence that loss of one or both
copies of the tumor suppressor Capicua (CIC) contributes to primary tumor relapse and metastatic progres-
sion, potentially offering a treatment target for castration-resistant prostate cancer (CRPC). Our work pro-
vides a resource for genetic, genomic, and biological studies employing two commonly-used prostate
cancer cell lines.
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Cultured cancer cell lines, such as the human-derived PC3 and LNCaP,
are critical for prostate cancer research. The androgen-dependent
LNCaP cell line (clone FGC) is derived from a lymph node metastasis
(Horoszewicz 1980; Horoszewicz et al. 1983), and the androgen-
independent PC3 cell line is derived from a bone metastasis (Kaighn
et al. 1979). Since their development, almost 40 yr ago, they have emerged
asmajor tools in prostate cancer research (with PubMed searches 15.01.17
for “PC3 AND prostate” and “LNCaP AND prostate” returning 3266 and
7080 hits, respectively).While these cell lines have been interrogated using
array- and sequencing-based technologies (Liu et al. 2008; Barretina et al.
2012; Spans et al. 2012; Klijn et al. 2015), whole-genome sequences for the
PC3 and LNCaP cell lines have not been published. Albeit currently rel-
atively costly, WGS offers better coverage than exome sequencing, and
improved detection of single nucleotide and small indel mutations and
structural variants such as copy number alterations (Meynert et al. 2014;
Belkadi et al. 2015; Warr et al. 2015).
MATERIALS AND METHODS
Cell lines
PC3 (ATCC CRL-1435) and LNCaP clone FGC (ATCC CRL-1740;
hereafter termed LNCaP) prostate cancer cell lines were obtained from
the American Type Culture Collection (ATCC, Rockville, MD), and
maintained in Roswell Park Memorial Institute RPMI 1640 medium
(Invitrogen, Carlsbad, CA) with 10% Fetal Calf Serum (Thermo Fisher
Scientiﬁc,Waltham,MA), supplementedwith100U/mlpenicillinGand
100 ng/ml streptomycin (Invitrogen). All cell lines were passaged at 2–
3-d intervals on reaching 70% conﬂuency using TrypLE Select (Invi-
trogen). Cell morphology and viability were monitored by microscopic
observation and regularMycoplasma testing was performed (Universal
Mycoplasma Detection Kit; ATCC).
Sequencing
DNAwas extracted using a QIAampDNAmini kit (QIAGEN, Hilden,
Germany) from low passage (passage four) PC3 and LNCaP cell lines,
cultivated from frozen stocks obtained directly from the ATCC. Se-
quencing was performed by Macrogen (Seoul, South Korea). Brieﬂy,
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library preparation was performed using a TruSeq Nano DNA kit
(Illumina, San Diego, CA) with a target insert size of 350 bp. Paired-
end libraries (150 bp) were sequenced using a HiSeqX sequencer
(Illumina). Base calls were converted into FASTQ ﬁles using bcl2fastq
v2.15.0 and provided to our laboratory.
Normal prostate data
Raw data from normal human prostate samples were obtained from
the National Institutes of Health’s Cancer Genome Atlas (The
Cancer Genome Atlas Research Network 2015) (NCBI dbGaP:
phs000178.v9.p8). These included a WGS sample (PCAWG.e22e63de-
c436-43c0-a595-022622c1fe06) and three RNA-seq samples (120215-
UNC10-SN254-0327-AC0CMCACXX-ACTTGA-L005, 120502-UNC14-
SN744-0235-BD0YUTACXX-ACTTGA-L005, and 130221-UNC9-
SN296-0338-BC1PYCACXX-TGACCA-L008). TheWGS ﬁle (101 bp
paired-end library; 950 M reads) was provided as an unaligned BAM
(uBAM) ﬁle and converted to FASTQ ﬁles using bamUtils v1.0.14
genome.sph.umich.edu/wiki/BamUtil.
Data processing
Raw reads (FASTQ) were trimmed using scythe v0.994 github.com/
vsbuffalo/scythe, with default settings, to remove low quality bases and
read-pairs, and contaminating adapter sequences.
Mapping of genome reads to reference genome: FASTQ ﬁles were
mapped to human reference genome GRCh38 build 82 (the reference
genome in all subsequent analyses) usingBWA-MEM(Li 2013), available
in v0.7.12-r1039, and a sorted BAM ﬁle was generated by SAMtools
v1.3.1 (Li et al. 2009). Genome coverage was estimated using QualiMap
v2.2.1 (García-Alcalde et al. 2012; Okonechnikov et al. 2016).
de novo genome assembly: PC3 and LNCaP genomes were assembled
de novo using SGA v0.10.15 (Simpson and Durbin 2012) (available at
github.com/jts/sga), as outlined in the user manual, except that assem-
bled contigs were indexed using BWA-MEM (Li 2013) instead of the
bundled Python script sga-align (calls BWA sample: bwa mem -t $CPU
ﬁnal-contigs.fa $READ1$READ2 | samtools view -F2304 -b -o reads.bam-).
Resulting scaffolds were gap ﬁlled using “sga gapﬁll” and error-
corrected FASTQ reads. The genome assemblies (gapﬁlled scaffolds)
were evaluated using QUAST v4.3 (Gurevich et al. 2013) and the
human reference genome. Genes of interest were interrogated in the
assembled genomes using BLAST, via a local instance of Sequence-
Server v1.0.9 (Priyam et al. 2015), and GMAP v2016-11-07 (a genomic
mapping and alignment program for mRNA and EST sequences) (Wu
and Watanabe 2005).
Single nucleotide variant (SNV) and short indel calling: Samtools
v1.3.1 mpileup and bcftools (Li et al. 2009) were used to interrogate
indexed BAM ﬁles of reads aligned to the reference genome and gen-
erate a VCF (Variant Call Format) ﬁle of SNVs and short indel variants.
Variants (likely to be common germline variants) present in HapMap
(Gibbs et al. 2003), 1000 genomes phase 3 (2504 human genomes)
(Sudmant et al. 2015), and the National Heart Lung and Blood Insti-
tutes Exome Sequencing Project (Tennessen et al. 2012) (bundled var-
iant data ﬁle available at https://goo.gl/mEogvD) were excluded.
Next, variant ﬁles (VCF) were ﬁltered using SnpSift (Cingolani et al.
2012a) with the following parameters: QUAL $ 200 && DP $ 30;
where QUAL denotes minimum variance conﬁdence and DP total
depth threshold. Filtered variants were annotated using SnpEff v4.3g
(Cingolani et al. 2012b).
Copy number variation (CNV) calling: To screen PC3 and LNCaP
genomes for CNV, we employed the R package “cn.mops” (Copy
Number estimation by a Mixture Of PoissonS) (Klambauer et al.
2012). Brieﬂy, paired-end genome reads from PC3 and LNCaP were
aligned to the reference genome and compared with normal prostate
reads to obtain genome-wide read-depth proﬁles. Custom R scripts
were used to parse the output.
Gene expression potential analysis:We interrogatedpublicly available
transcriptome data from PC3 (Wang et al. 2015) (NCBI GEO:
GSE65112) and LNCaP cells (Metzger et al. 2016) (NCBI GEO:
GSE64529). In addition, transcriptome data from normal prostate sam-
ples were obtained from TCGA (see above). Brieﬂy, paired-end reads
were trimmed using scythe, and aligned to human reference genome
GRCh38 build 82 using the spliced-read mapper TopHat (v2.0.9) (Kim
et al. 2013) and reference gene annotations to guide the alignment.
Raw gene counts were computed from the generated BAM ﬁles by
featureCounts v1.4.5-p1 (Liao et al. 2014), counting exon features of
the gene annotation ﬁle (gtf) in order to include noncoding RNA genes.
FeatureCounts output ﬁles were analyzed using the R programming
language (v.3.2.2) (R Core Team 2013). Raw counts were normalized by
TrimmedMean ofM-values (TMM) correction (Robinson and Oshlack
2010; Robinson et al. 2010). The expression of genes in normal prostate,
LNCaP, and PC3 was assessed using the Universal exPression Code
(UPC) method (Piccolo et al. 2013), available in the R package
“SCAN.UPC”. This method estimates the active/inactive state of
genes in a sample, where a UPC value. 0.5 indicates that a gene is
actively transcribed.
cBioPortal analysis: Data on copy number alterations in prostate
cancer tumor tissue were obtained using the cBioPortal tool (www.
cbioportal.org) (Cerami et al. 2012; Gao et al. 2013) with the following
parameters: “GENE: HOMDEL HETLOSS;”, where “GENE” denotes a
gene symbol. Clinical information was also downloaded and the data
further analyzed using custom R scripts.
The following cBioPortal prostate cancerdata setswere interrogated:
‘NEPC (Trento/Cornell/Broad 2016)’ (34 primary and 73 metastatic
tumors) (Beltran et al. 2016), ‘Prostate (Broad/Cornell 2013)’ (55 pri-
mary tumors and 1 metastatic tumor) (Baca et al. 2013), ‘Prostate
(FHCRC, 2016)’ (19 primary and 130 metastatic tumors) (Kumar
et al. 2016), ‘Prostate (MICH), (11 primary and 47 metastatic tumors)
(Grasso et al. 2012), ‘Prostate (MSKCC2010)’ (157 primary and37met-
astatic tumors) (Taylor et al. 2010), ‘Prostate (MSKCC 2014)’ (101 pri-
mary and 3 metastatic tumors), (Hieronymus et al. 2014), ‘Prostate
(SU2C)’ (150 metastatic tumors) (Robinson et al. 2015), and ‘Prostate
(TCGA)’ (492 primary and 1 metastatic tumors) (The Cancer Genome
Atlas Research Network 2015).
Kaplan–Meier survival analysis: Kaplan–Meier survival analysis was
performed to compare disease-free survival (DFS) in patient
groups stratiﬁed by CNVs. DFS is deﬁned as the time to either
recurrence or relapse, second cancer, or death (Gill and Sargent
2006). In the context of prostate cancer, DFS is a suitable surrogate
for overall survival (OS), given that metastatic disease is not cur-
able and recurrence of disease would be expected to contribute
signiﬁcantly to mortality.
‘The Prostate (MSKCC2010)’, ‘Prostate (MSKCC2014)’, and ‘Pros-
tate (TCGA)’ cBioPortal data sets were interrogated. Kaplan–Meier
survival analysis (Rich et al. 2010) was performed using the R package
“survival” (Therneau 2013), ﬁtting survival curves (survﬁt) and
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computing log-rank P-values using the survdiff function, with r =
0 (equivalent to the method employed by UCSC Xena; see goo.gl/
4knf62). Survival curves were plotted where survival was signiﬁ-
cantly different between two groups (log-rank P# 0.05). Groups
with ,10 samples with recorded events were considered unreliable
(Mallett et al. 2010).
Gene ontology term enrichment analysis
Gene enrichment analyses were performed using DAVID (Database
for Annotation, Visualization and Integrated Discovery) (Huang
et al. 2009a). All gene groups are potentially informative, despite
lower rankings, and serve to guide biological interpretation (Huang
et al. 2009b).
Data availability
The genome reads reported in this paper have been deposited in
the BioProject database as PRJNA361315 (PC3) and PRJNA361316
(LNCaP).Codeused to generate thedata andCNVanalysis outputﬁles
(tabulated text ﬁles) are available at github.com/sciseim/PCaWGS.
Genome assemblies (FASTA format) (Seim 2017a,b), and ﬁltered and
annotated single-nucleotide and indel variation data ﬁles (VCF for-
mat) (Seim 2017c), have been deposited at Zenodo. A BLAST server is
available at http://ghrelinlab.org.
RESULTS AND DISCUSSION
WGS
PC3 and LNCaP prostate cancer cells were obtained directly fromATCC,
cultured for four passages, and 150 bppaired-end reads obtained using an
Illumina HiSeqX sequencer. Following read trimming, 1.53 billion reads
from PC3 were retained, of which 99.9% could be aligned to the Ensembl
GRCh38.82 human reference genome at 71 · mean coverage (Figure
1A). Similarly, we obtained 1.49 billion trimmed reads from LNCaPwith
a 99.9% alignment rate and mean coverage of 69 · (Figure 1B).
We also performed de novo genome assembly to allow character-
ization of whole-gene loci by BLAST and othermappers. The ﬁnal, gap-
ﬁlled PC3 genome assembly consisted of 1.66 M scaffolds (largest
scaffold 692.4 kb) with an N50 of 23.3 kb and an NG50 (number of
sequences with lengths equal to or larger than N50) of 22.4 kb. The
LNCaP assembly consisted of 1.70 M scaffolds (largest scaffold
536.0 kb) at an N50 value of 44.4 kb and NG50 of 45.0 kb.
Single-nucleotide and indel variation
Afterexcludingcommongermlinesequencevariants(SNVsandshort indels),
ﬁltering by SnpSift (Cingolani et al. 2012a), and annotation by SnpEff
(Cingolani et al. 2012b), we identiﬁed in LNCaP 0.94 M and in PC3
0.56 M sequence variants (SNVs and short indels) that were private or
Figure 1 Read-depth across chromosomes in the (A) PC3 and (B) LNCaP prostate cancer cell lines. The red dotted line indicates mean genome-
wide sequencing coverage (X).
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unique to the particular cell line (Table 1). As expected, the majority of
variants were found in noncoding regions.
In particular, we noted that LNCaP had a larger number of
stop_gained events, which are changes predicted to confer nonsense
mutations and result in nonfunctional proteins or proteins with
reduced function (Table 1). In LNCaP, SNVs and indel variants
contributed 378 stop_gained events in 209 genes. We next identiﬁed
biological processes overrepresented in this gene set (Table 2). This
included a C/T transition at amino acid position 318 of menin
(MEN1) (c.T954A in NCBI RefSeq NM_000244). Somatic inactivat-
ing mutations of menin are found in endocrine cancers (Falchetti
et al. 2009), suggesting that MEN1 is a tumor suppressor gene.
However, it has recently been reported that MEN1 is an oncogene
in prostate cancer. Menin interacts with the androgen receptor and
patients with overexpression of MEN1 show poor OS (Malik et al.
2015). TheMEN1 SNV is present in an LNCaP sample interrogated
by whole-exome sequencing (Taylor et al. 2010). Therefore, it is not
likely to be a sequencing or data processing artifact. The functional
regions of menin are currently not known, thus, the effect of the
LNCaP premature stop codon event cannot be predicted. Interro-
gation of eight cBioPortal data sets suggests that inactivating muta-
tions in the coding sequence ofMEN1 in prostate cancer is unique to
LNCaP (data not shown); however, it is possible that distinct patient
populations possess this variant (e.g., see Lindquist et al. (2016)).
In PC3, 58 stop_lost events (Table 1) in 20 genes, (AHNAK2,
DNAH6, FAT3, GOLGA6L3, GOLGA6L9, HLA-A, HLA-B, HLA-
DRB1, HLA-DRB5, HOXA9, IL1A, ITPR2, MEGF6, MUC19, OR8K3,
PRPF3, PRSS1, PTPRD, USP17L11, and USP17L18) were observed.
There was a signiﬁcant enrichment for HLA class II antigen presenting
genes associated with the immune response (Table 3; Fisher’s exact P
0.05). It has recently been shown that the PC3, LNCaP, and DuPro (but
not the DU145) prostate cancer cell lines and prostate cancer tissues
express HLA class II molecules (Younger et al. 2008; Doonan and
Haque 2015). However, we could not identify any prostate cancer
patients with stop_lost events in these genes using the cBioPortal tool
(Cerami et al. 2012; Gao et al. 2013) (data not shown).While evasion of
the antitumour immune response is an emerging research area (Drake
2010; Corrales et al. 2016), caution should be exercised when consid-
ering the use of PC3 cells in these studies. Sequence variant analysis and
interrogation of the PC3 de novo genome assembly by BLAST and
GMAP conﬁrmed that the tumor suppressor p53 (TP53) is inactivated
by a single frameshift event (p.A138fs; indel; c.4955A in NCBI RefSeq
NM_000546) (Carroll et al. 1993) (Figure 2A).
PC3 shared 0.26 M sequence variants (166,912 SNVs and 89,919
indels) with LNCaP, and 21 of these constituted stop_lost events (Table
1). Overrepresented biological processes in PC3 and LNCaP included
“O-glycan processing” (the mucins MUC3A and MUC6) and “extra-
cellular matrix disassembly” (the trypsinogens PRSS1 and PRSS2)
(Table 2). Interestingly, while we have identiﬁedMUC3A stop_gained
events in PC3 and LNCaP, cell lines generated fromCaucasian patients,
a recent study suggests that MUC3A protein-changing variants are rare
in Caucasians and predominant in African Americans, the subpopula-
tion with the highest prevalence of prostate cancer, where MUC3A
changes are observed in 88% of patients (Lindquist et al. 2016).
Taken together, these data indicate that protein-coding genes in
LNCaP are perturbed extensively by point and indel mutations. Even
n Table 1 SNV and indel variant-calling statistics of the prostate cancer cell lines PC3 and LNCaP
PC3 Private LNCaP Private Shared
Number and percentage of variants by type
SNVs 318,380 34.0% 404,282 72.1% 166,912 65.0%
Indels 618,149 66.0% 156,182 27.9% 89,919 35.0%
Number of events by type
39-UTR 15,572 10,500 3938
59-UTR premature start codon 211 289 49
59-UTR 2613 1868 692
Conservative_inframe_deletion 39 22 7
Conservative_inframe_insertion 468 119 72
Disruptive_inframe_deletion 62 19 7
Disruptive_inframe_insertion 172 64 44
Downstream_gene 107,761 56,728 29,770
Frameshift 276 167 44
Intergenic_region 563,630 326,261 175,014
Intron 916,272 576,268 191,182
Missense 3520 5717 1667
Non_coding_transcript_exon 5848 3846 2091
Non_coding_transcript 18 10 1
Protein_protein_contact 120 17 5
Sequence_feature 7978 5930 1457
Splice_acceptor 80 131 21
Splice_donor 56 138 17
Splice_region 1313 1174 437
Start_lost 16 14 3
Stop_gained 58 378 29
Stop_lost 25 4 9
Structural_interaction 1160 808 1
Synonymous 2402 2727 81
Upstream_gene 107,281 57,447 1301
Common germline variants were excluded and variants were further ﬁltered using SnpSift, with a total depth threshold at 30 (DP $ 30) and a minimum variance
conﬁdence of 200 (QUAL $ 200), and annotated by SnpEff. SNV, single nucleotide variant; UTR, untranslated region.
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n Table 2 Signiﬁcantly overrepresented biological processes associated with sequence variants contributing stop_gained events in the
PC3 and LNCaP prostate cancer cell lines
GO Term Genes
Fisher’s
Exact P
PC3 private sequence variants
Detection of bacterium HLA-DRB1, HLA-A, HLA-DRB5, HLA-B 5.1E210
Antigen processing and presentation HLA-DRB1, HLA-A, HLA-DRB5, HLA-B 2.4E207
Interferon-g-mediated signaling pathway HLA-DRB1, HLA-A, HLA-DRB5, HLA-B 6.7E207
Immune response HLA-DRB1, HLA-A, HLA-DRB5, HLA-B, IL1A 4.7E205
Antigen processing and presentation of endogenous peptide
antigen via MHC class I via ER pathway, TAP-independent
HLA-A, HLA-B 2.9E206
Regulation of interleukin-10 secretion HLA-DRB1, HLA-DRB5 2.9E206
Regulation of interleukin-4 production HLA-DRB1, HLA-DRB5 5.8E206
Protection from natural killer cell mediated cytotoxicity HLA-A, HLA-B 9.6E206
Immunoglobulin production involved in immunoglobulin
mediated immune response
HLA-DRB1, HLA-DRB5 9.6E206
Humoral immune response mediated by circulating immunoglobulin HLA-DRB1, HLA-DRB5 2E205
Antigen processing and presentation of exogenous peptide antigen via
MHC class I, TAP-independent
HLA-A, HLA-B 3.5E205
T-helper 1-type immune response HLA-DRB1, HLA-DRB5 6.3E205
Positive regulation of T cell mediated cytotoxicity HLA-A, HLA-B 7.5E205
Inﬂammatory response to antigenic stimulus HLA-DRB1, HLA-DRB5 0.0001
Antigen processing and presentation of peptide or polysaccharide
antigen via MHC class II
HLA-DRB1, HLA-DRB5 0.00013
Negative regulation of interferon-g production HLA-DRB1, HLA-DRB5 0.00036
Positive regulation of insulin secretion involved in cellular
response to glucose stimulus
HLA-DRB1, HLA-DRB5 0.00039
Antigen processing and presentation of peptide antigen via MHC class I HLA-A, HLA-B 0.00041
Negative regulation of T cell proliferation HLA-DRB1, HLA-DRB5 0.00063
Protein tetramerization HLA-DRB1, HLA-DRB5 0.00074
Antigen processing and presentation of exogenous peptide antigen via
MHC class I, TAP-dependent
HLA-A, HLA-B 0.0018
Type I interferon signaling pathway HLA-A, HLA-B 0.0019
T cell costimulation HLA-DRB1, HLA-DRB5 0.0028
Antigen processing and presentation of exogenous peptide antigen via
MHC class II
HLA-DRB1, HLA-DRB5 0.0038
Protein deubiquitination USP17L18, USP17L11 0.0044
LNCaP private sequence variants
Bundle of His cell to Purkinje myocyte communication GPR155, GNAS, CBR3, CHL1 0.00012
Response to nitrosative stress PRKCQ, CD3E, NLRP3 0.00068
Cognition FPGT-TNNI3K, TNNI3K 0.0008
Interleukin-1 b production MEN1, NTRK3, PAX6, PRKDC 0.0011
Positive regulation of interleukin-4 production LAMA2, PRKCQ, ROBO1, PAX6,
SPTBN1, CHL1
0.0012
Humoral immune response mediated by circulating immunoglobulin GCLC, DUSP6 0.0023
Type B pancreatic cell differentiation NTRK3, AP1B1, FREM2, ROBO1,
PRKDC, TBC1D32
0.004
Negative regulation of protein phosphorylation LRP1, STAB1, VTN, SSC4D, AMN, DMBT1 0.0042
Axon guidance NLRP3, CASP1 0.0076
Heart development LAMA2, FREM2, ROBO1, STAB1, ITGB4, VTN,
CERCAM, COL16A1, CHL1, AOC3
0.014
Receptor-mediated endocytosis EXO1, HLA-DQB1 0.016
Cell adhesion MEN1, PAX6 0.027
Shared sequence variants (PC3 and LNCaP)
Sensory perception of taste TAS2R43, TAS2R31 0.00048
Detection of chemical stimulus involved in sensory
perception of bitter taste
TAS2R43, TAS2R31 0.00092
O-glycan processing MUC3A, MUC6 0.0021
Digestion PRSS2, PRSS1 0.0023
Extracellular matrix disassembly PRSS2, PRSS1 0.0033
Stop_gained events are denoted changes predicted to confer nonsense mutations and result in nonfunctional proteins or proteins with reduced function. Gene
enrichment analysis was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery). MHC, major histocompatibility complex; ER,
endoplasmic reticulum; TAP, transporter associated with antigen processing.
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after ﬁltering steps, our LNCaP data (at passage four from the ATCC
stock) reveal a clear difference in the number of particular variant events
compared to PC3. However, previous exome sequencing work suggests
that the genome of the parental LNCaP strain sequenced here (clone
FGC) and its derived strains are inherently unstable (Spans et al. 2012,
2014), and this could give rise to the apparently high mutation rate in
protein-coding sequences. As with studies of the HeLa genome (Adey
et al. 2013; Landry et al. 2013), further genome sequencing efforts are
warranted to investigate whether the variants reported here are somatic
mutations found in particular LNCaP strains, or if they represent pre-
existing subpopulations within the parental LNCaP strain. In the fu-
ture, single-cellWGS is likely to resolve this issue. Nevertheless, LNCaP
and PC3 appear to have distinct SNV and indel proﬁles.
Putative gene loss
Most human cancers have CNVs, which impact upon gene dosage
through loss or gain of whole chromosomes or chromosome segments
(Hanahan andWeinberg 2011). Previous studies have described CNVs
in PC3 and LNCaP using targeted techniques, such as exome sequenc-
ing. However, WGS, together with continuously updated gene anno-
tations, offers improved detection of copy number changes (Meynert
et al. 2014; Belkadi et al. 2015; Warr et al. 2015).
CNVswere identiﬁedusing theRpackage cn.mops (Klambauer et al.
2012). In particular, wewished to identify genes that are lost in PC3 and
LNCaP. The absence of this information can misinform even the most
well-designed in vitro or cell line xenograft experiment (e.g., where a
gene in an important pathway is lost). In the context of CNV analysis,
wewere interested in identifying putative homozygous deletions (CNV=0;
CNV0 events), i.e., genes that are inactivated by partial or complete gene
deletion. To inform this analysis, we also considered the transcriptional
potential of each gene by analyzing publicly available transcriptome
(RNA-seq) data from normal prostate, LNCaP, and PC3. Genes with a
UPC value of 0.5 were considered inactive (Piccolo et al. 2013).
Althougha largenumberof SNVsand indelvariationswereobserved
in LNCaP, only a single homozygous deletion event (CNV0) was
observed in this cell line. In the complex Prader-Willi gene locus there
was a putative loss of PWRN1, a gene associatedwith epigenetic reprog-
ramming during spermatogenesis (Wawrzik et al. 2009) (Table 3).
In contrast to LNCaP, 39CNV0 eventswere found in PC3 (Table 3).
CNV of the Y chromosome was evident from the PC3 sequence cov-
erage (Figure 1A). In agreement with previous studies employing
cDNA microarrays (Clark et al. 2003) and multicolor ﬂuorescence in
situ hybridization (Aurich-Costa et al. 2001), our CNV analysis
revealed that large regions of the Y chromosome (including eight genes)
were deleted in PC3 (Table 3). Several genes on chromosome
5 (CDH18, CTNNA1, LRRTM2, and SIL1), chromosome 10 (DYDC1,
DYDC2, FAM213A, LIPJ, MAT1A, PTEN, RNLS, SH2D4B, and
TSPAN14), and chromosome 17 (ATP6V0A1, DHX58, GHDC, HCRT,
HSPB9,KAT2A,KCNH4,MIR548AT, PTRF, RAB5C, STAT3, STAT5A,
and STAT5B) have also previously been reported to be deleted in PC3
(Liu et al. 2008; Krohn et al. 2012; The Cancer Genome Atlas Research
Network 2015; Ibeawuchi et al. 2015).
Clinical observations and experimental studies indicate that the
growth hormone receptor (GHR) mediates the development and pro-
gression of cancer (Brooks and Waters 2010), and GHR expression is
elevated in prostate cancer cell lines and tissues (Chopin et al. 2002;
Weiss-Messer et al. 2004). Interestingly, we noted that the genes encod-
ing the classical growth hormone receptor signaling molecules STAT3
(STAT3) and STAT5 (STAT5A and STAT5B) were lost in PC3 cells.
Thus, autocrine GHR actions are likely to be associated with alternative
signaling pathways (Barclay et al. 2010) in PC3. Loss of STAT3 in PC3
has been ﬁrmly established experimentally (Yuan et al. 2005; Pencik
et al. 2015), and there is evidence to suggest that STAT3 suppresses
prostate cancer metastasis and confers a good prognosis (Pencik et al.
2015).
We identiﬁed a homozygous deletion event spanning four genes
(CIC, PAFAH1B3, PRR19, and TMEM145) on chromosome 19 in PC3
(Figure 3A). In LNCaP, a genome coverage plot of reads ﬂanking this
region revealed a putative heterozygous event (CNV1; loss of a single
copy of the same genes) (Figure 3B). Of these four genes, the mamma-
lian homolog of Drosophila CIC (Jiménez et al. 2012) is particularly
interesting. Capicua is a transcriptional repressor of cancer metastasis
in a number of cancers (Choi et al. 2015; Okimoto et al. 2017). Recent
WGS data also suggests that CIC is lost in PC3 cells (Iorio et al. 2016).
Homozygous deletions of CIC have been reported in neuroblastoma
(Nagaishi et al. 2014; Fransson et al. 2016), and a homozygous deletion
Figure 2 Overview of a p53 (TP53) sequence variant in the PC3 prostate cancer cell line. (A) Genome browser display showing an indel event in
the PC3 p53 gene (TP53). (B) Sequence alignment of TP53 in the PC3 genome and the reference genome assembly (Ensembl GRCh38 build 82).
An indel is indicated in red. (C) Sequence alignment of TP53 protein products encoded by PC3 and the reference transcript NM_000546. An indel
results in a frameshift (p.A138fs) and a truncated protein in PC3. chr, chromosome; SNV, single nucleotide variation.
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of CIC in a subpopulation of H1975 human nonsmall cell lung cancer
cell line xenografts rendered them highly metastatic (Okimoto et al.
2017). We interrogated 75 cBioPortal data sets from diverse tumors,
conﬁrming that one or two copies of CIC are lost in many cancer types
(see Supplemental Material, Figure S1).
CIC is abundantly expressed in normal prostate tissue, whereas its
expression is reduced in primary tumors and ablated in metastatic
prostate cancer (Choi et al. 2015). To characterize the potential clinical
signiﬁcance of CIC deletions in prostate cancer, we further examined
1311 tumors from eight data sets using the cBioPortal tool. While
homozygous deletion events of the four genes deleted in PC3 cells were
rare, a substantial fraction of prostate tumors harbored heterozygous
deletions of these genes (Figure 3C). Approximately 6% of primary
prostate tumors had heterozygous deletions and 2% had homozygous
deletions of CIC, whereas 21% of metastatic tumors had homozygous
CIC deletions and 2% heterozygous deletions (Figure 3D).
Prostate cancer relapse or recurrence frequently results in incurable
metastasis, ultimately causing patient death (Wu et al. 2014; Weiner
et al. 2016). As CIC deletions were more frequent in metastatic tumors,
we reasoned that deletion of one or both copies of CIC is a means by
which primary tumors in patients that eventually develop metastatic
lesions achieve increased ﬁtness and survival. The association between
CIC homozygous deletion events andDFS in primary tumors could not
be reliably assessed due to the low number (n = 2) of patients with
recorded relapses; however, patients with primary prostate tumors with
one lost copy of CIC (heterozygous deletion events) had a signiﬁcantly
worse outcome (P = 0.018, log-rank test) (Figure 3E). Similarly, OS is
signiﬁcantly worse in advanced-stage gastric cancer patients with low
CIC expression (Okimoto et al. 2017).
A recent study comparing PC3 and LNCaP reported that the long
form of the CIC protein (CIC-L) was not expressed and that the short
form (CIC-S) was expressed at extremely low levels in PC3 cells (Choi
Figure 3 Deletion of the tumor suppressor Capicua (CIC) in prostate cancer (A) Genome browser display showing a CNV0 event (red dotted line)
on chromosome 19 that spans CIC, PAFAH1B3, PRR19, and TMEM145 in the PC3 prostate cancer cell line. (B) Plot of putative chromosomal loss
spanning the four-gene region in LNCaP (left panel) and PC3 (right panel). The x-axis represents the genomic position and the y-axis the number
of normalized counts. (C) Loss of the chromosome 19 region encompassing CIC, PAFAH1B3, PRR19, and TMEM145 in the ‘Prostate FHCRC
2016’ cBioPortal data set. Individual tumor samples are shown in columns and genes in rows. (D) CIC copy number alterations in primary and
metastatic prostate cancer samples from eight clinical data sets interrogated using cBioPortal. (E) Disease-free survival in primary prostate cancer
patients with loss of a single CIC gene copy (n = 13 relapse events) is signiﬁcantly decreased compared to those without any CIC deletion events.
‘The Prostate (MSKCC 2010)’, ‘Prostate (MSKCC 2014)’, and ‘Prostate (TCGA)’ cBioPortal data sets were interrogated. P-values were calculated by
Kaplan–Meier analysis (log-rank test). Time denotes years. CNV0, homozygous deletion; CNV1, heterozygous deletion; WT, wild-type.
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et al. 2015). Our CNV analysis, employingWGS reads, interrogation of
the de novo PC3 assembly using BLAST and GMAP, and analysis of
RNA-seq reads mapped to the reference genome, failed to detect an
intact CIC gene in PC3. We sequenced low-passage PC3 cells sourced
directly from ATCC and speculate that the previous study (Choi et al.
2015) detected low-level gene expression by PC3 subpopulations with
intact CIC resulting from genetic drift during prolonged subculture
(passaging; see Festuccia et al. (1999); Li et al. (2008)).
Taken together, these data suggest that although a rare event in
prostate tumors, homozygous deletion of CIC is not an idiosyncrasy of the
PC3 cell line. Moreover, loss of a single gene copy of CIC is relatively
common in prostate cancer. We speculate that disruption of one or both
copies of CIC renders prostate cancer patients susceptible to an adverse
disease outcome. A previous study employing forced overexpression of
CIC in PC3 and LNCaP demonstrated that CIC is repressed by a trio of
microRNAs (Choi et al. 2015). AlteredMAPK signaling through the ERK
pathway also suppresses endogenous CIC in lung cancer (Okimoto et al.
2017). Collectively, our data raise the possibility that the combination of
microRNA repression, altered ERK signaling, and somatic events in the
CIC locus promote tumorigenesis and confer a poor disease outcome.
Relevance of ﬁndings
In summary, we provide genome sequence data for PC3 and LNCaP,
prostate cancer cell lines commonly employed in cancer research.
These data contribute to a catalog of cancer genomes, adding to
recentwhole-transcriptome sequencing, pharmacological proﬁling, and
whole-exome sequencing efforts (Barretina et al. 2012; Klijn et al. 2015;
Iorio et al. 2016) aimed at enhancing our understanding of human
disease. For example, the phenomenon of androgen independence in
prostate cancer has intrigued scientists for decades. Of the two cell lines
interrogated in our study, PC3 is androgen-independent, whereas the
LNCaP strain sequenced (LNCaP-FGC) is androgen-dependent. Re-
cent work, including an investigation of 150 patients with metastatic
CRPC (Robinson et al. 2015), suggests that anomalies (mutations, am-
pliﬁcations, and deletions) in a number of genes in the androgen re-
ceptor pathway play a role in the transition to androgen independence.
We speculate that future work—employing WGS, RNA-sequencing,
epigenetic proﬁling, and similar high-throughput methods—on a large
number of cell lines and clinical samples is likely to identify genes critical
for androgen independence. For instance, an androgen-independent
strain of LNCaP (LNCaP-LNO) has been developed from cultures of
an early passage of the LNCaP cells sequenced in our study (LNCaP-
FGC) (van Steenbrugge et al. 1991). LNCaP-LNO and LNCaP-FGC
were compared at the gene expression level (Oosterhoff et al. 2005);
hinting that speciﬁc gene mutations or copy number events render
LNCaP-LNO cells androgen-insensitive.
Raw reads (see Data availability in Materials and Methods) and
sequence (SNV and indel) and CNV data are made available. We have
generated de novo genome assemblies of both cell lines, allowing genes
of interest to be investigated further, enabling, for example, the valida-
tion of gene loci associated with novel transcripts obtained fromTrinity
de novo transcriptome analysis (Grabherr et al. 2011; Haas et al. 2013).
In addition, the genomes can be interrogated using a BLAST server,
available at http://ghrelinlab.org. We acknowledge the limitations of
short-insert (350 bp) genome sequencing, particularly when resolving
complex repetitive or heterozygous regions (Rhoads and Au 2015;
Merker et al. 2016). However, we anticipate that as sequencing becomes
increasingly affordable, our sequencing efforts will complement future
long-read genome assembly work and prove useful when correcting for
errors (sequence polishing).
Finally, we reveal that one or both copies of CIC, a tumor metastasis
suppressor gene, are frequently lost in prostate cancer and could drive
metastatic CRPC.We anticipate that further biological insights into the
role of Capicua in prostate cancer will shortly be gained by the research
community, in line with the ethos of G3: Genes, Genomes, Genetics
Genome Reports.
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